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Figure 1. Representative MtbTMPK inhibitors
In 2012, gram-positive bacterial TMPK inhibitors with picomolar activity were reported and further optimization of their physico-chemical properties and pharmacokinetics afforded a class of promising antibacterial agents. 14 Since no evaluation of these analogues on MtbTMPK was reported, we set out to resynthesize compound 1, which featured as the parent inhibitor for lead 7 generation, and found it to be a fairly potent MtbTMPK inhibitor (Ki = 1.5 µM), comparable with the most potent nucleoside MtbTMPK inhibitors. 9 Encouraged by this result, we decided to further investigate its SAR (Figure 2 ). We first changed the configuration of the lipophilic biaryl ether from the meta-to para-position of the internal phenyl group (compound 2). In order to explore the chiral preference of the enzyme, the pure enantiomers of 1 and compound 2 (compounds 3-6) were prepared. In two more analogues (7 and 8) the piperidine ring was substituted for a pyrrolidine ring. To explore the effect of additional distance and flexibility between the thymine and piperidinyl or pyrrolidinyl rings, analogues having a methylene linkage inserted between these heterocycles (9) (10) (11) (12) were prepared.
In two final analogues (13 and 14) the tertiary amine was replaced with a tertiary amide in order to investigate the importance of the positively charged nitrogen on the piperidine ring. Based on the established X-ray crystal structure of MtbTMPK, we performed molecular modeling studies on these piperidinyl thymine analogues in order to better understand the observed SAR and to shed light on further modifications. 8 Figure 2 . Overview of non-nucleoside thymine derivatives synthesized in this study.
Results and Discussion

2.1.Chemistry
In the original synthesis of the hit compound 1, 14 the key intermediate 15 is prepared using the highly moisture-sensitive isocyanate species 17, which was obtained from methyl methacrylate using a potentially hazardous multi-step synthesis. 15 In order to access intermediate 15 by an easier and safer means, alternative synthetic routes were explored. According to Rejman and coworkers, 15 there are two alternative methods for the synthesis of the 1-(piperidin-3-yl)thymine 15 in addition to the cyclization between substituted isocyanate 17 and primary amine 16 mentioned above. The first method connects the piperidine and thymine rings using a Mitsunobu reaction, the second one involves an alkylation reaction (Scheme 1). 16 9
In the Mitsunobu reaction, thymine can react as an ambident nucleophile yielding a mixture of N-and O-linked isomers. Therefore, the N3-position of thymine was protected with a benzoyl- 19) or a benzyloxymethyl- 20) as to avoid formation of the N3regioisomer. 17 Despite using the conditions for the Mitsunobu reaction as recommended by Rejman and coworkers, 16 no product was obtained. Further attempts to optimize the reaction conditions proved fruitless. Scheme 1. Three routes towards piperidinylthymine: isocyanate based pyrimidine synthesis, Mitsunobu reaction and alkylation using a mesylate
The alkylation reaction between thymine and mesylate (21) 18 is typically performed at high temperature (e.g., 100 ℃ or 120 ℃) under basic condition (NaH or Cs 2 CO 3 ) with the best obtained yield being 15%. 16 In an attempt to increase the yield of the alkylation, a first trial was conducted using N3-Bz-thymine (19 17 ) and cesium carbonate. Since compound 19 was hydrolyzed back to thymine under the reaction conditions, we switched to N3-BOM-protected thymine (20), which gave similar yields with cesium carbonate (21% and 16% at 100 ℃ and 130 ℃, respectively). A commonly observed feature of the alkylation reaction under these conditions was the large amount of unreacted thymine in the reaction mixture. A possible reason was the elimination of mesylate (21) into compounds 22 and 23 at high temperature (Scheme 2).
Based on these observations we could eventually raise the yield of product 25 substantially (to 51%) by lowering the reaction temperature to 80 ℃ with portionwise addition of the mesylate (21) and base (K 2 CO 3 ) over the course of the reaction (4 days). 19
Scheme 2: Alkylation of N3-protected thymine using piperidinylmesylates
The alkylation of compound 20 with the azacyclic mesylates (21 and 26 -31) provided the Boc-protected intermediates, which could be deprotected to give the required secondary amine intermediates (34 and 32-38). Next, reductive amination with aromatic aldehydes gave the N3-BOM-protected products, which were directly deprotected with TFA at 72 ℃ to afford the final products 1 -12. 20 The alkylation reaction was found to occur mostly by the S N 2 nucleophilic substitution reaction, which was demonstrated by chiral purity analysis (cf. experimental part and supplementary information).
For the synthesis of piperidinylamide analogues, corresponding aromatic carboxylic acids were condensed to 34, followed by hydrogenolysis to provide the final products 13 and 14 11 alongside their corresponding hemiaminals 13a and 14a, which could be further hydrolyzed to the final products (Scheme 3).
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26, m = 1, n = 0, R 27, m = 1, n = 0, S 21, m = 2, n = 0, rac. 28, m = 2, n = 0, R 29, m = 2, n = 0, S 30, m = 1, n = 1, rac. 31, m = 2, n = 1, rac. 20 1, m = 2, n = 0, R = R1, rac. 2, m = 2, n = 0, R = R2, rac. 3, m = 2, n = 0, R = R1, R 4, m = 2, n = 0, R = R2, R 5, m = 2, n = 0, R = R1, S 6, m = 2, n = 0, R = R2, S 7, m = 1, n = 0, R = R1, R 8, m = 1, n = 0, R = R1, S 9, m = 2, n = 1, R = R1, rac. 10, m = 2, n = 1, R = R2, rac. 11. m = 1, n = 1, R = R1, rac. 12. m = 1, n = 1, R = R2, rac. , m = 1, n = 0, R 33, m = 1, n = 0, S 34, m = 2, n = 0, rac. 35, m = 2, n = 0, R 36, m = 2, n = 0, S 37, m = 1, n = 1, rac. 38, m = 2, n = 1, rac. 
Biological evaluation and structure-activity relationship (SAR)
The inhibitory potency of compounds (1 -14) was evaluated on MtbTMPK catalytic activity (determination of the inhibitory constant Ki) and the results are summarized in Table 1 . A clear trend emerges in that the potency of the analogues with the meta-biphenyl ether tail is typically approximately 15-fold higher than that of their para-substituted congeners (comparing To assess the binding mode of these thymine analogues, docking of the piperidinyl thymines 3, 5 and 6, the pyrrolidinyl thymine 8 and both enantiomers of amide 13 was performed. The typical interactions found between the nucleobase of dTMP and MtbTMPK are likely to be conserved with compound 5 5 : (1) π-π stacking between the pyrimidine ring and Phe-70; (2) two hydrogen bonds between the O4-thymine and Arg-74; (3) a hydrogen bond between Asn-100 and the N3-thymine ring. Moreover, one extra hydrogen bond is formed through the oxygen of the meta-biphenyl ether and Arg-95 ( Figure 3 ), which may contribute to the higher affinity for the enzyme. The docking results indicate that none of the other compounds can form more polar interactions with the enzyme (Figure 4 ). The thymine ring of compound 3 forms similar interactions as compound 5 (with the Arg-74 and Asn-100 residues), but the meta-biphenyl ether of 3 lacks a hydrogen bond interaction with the enzyme, which may explain the inferior inhibitory potency of this R-enantiomer. Similar differences are also observed for compound 6
and 8, implying that the meta-biphenyl ether tail and piperidine ring are superior to the parasubstituted biphenyl ether tail and pyrroline ring, respectively. It is noteworthy that the aromatic tail of 3 is surrounded by residues Ala-35, Phe-36, Pro-37, Tyr 39, Asp-94, Arg-95 and Arg-160, which stabilize binding by hydrophobic interactions. Adding functional groups to this aromatic 14 tail may further increase interactions with those residues. Docking of the two enantiomers of compound 13 into MtbTMPK, indicates that the R-enantiomer may occupy a similar pose as the other inhibitors, while the S-enantiomer shows a completely different interaction with the enzyme resulting in a lower docking score (Figure 4 ). Considering the promising inhibitory activity of the racemate 13, it may be interesting to investigate the inhibitory potency of the pure enantiomers in the future. 
Conclusion
Inspired by the published Gram-positive bacterial TMPK inhibitor 1, we described the design and synthesis of a new series of non-nucleoside MtbTMPK inhibitors. A convenient and less hazardous synthetic method for 1-substituted azacyclo-thymine analogues has been developed.
By exploring different scaffolds, we have demonstrated that there are several spatial requirements with respect to the connection between the thyminyl and piperidinyl ring. First, analogues with S-stereochemistry were found to be superior inhibitors of MtbTMPK compared to their enantiomers. Furthermore, piperidinyl analogues have been shown to have a higher potency compared to their pyrrolidinyl counterparts. Additionally, the docking model suggests it is favourable to introduce functional groups to the meta-biphenyl ether tail. For compounds with amide moiety, more attention needs to be paid to the pure enantiomers. Finally we came to the conclusion that the best scaffold of this series is the known S-enantiomer (compound 5) 14a and future efforts should be focused on piperidinyl thymine analogues with S-stereochemistry combined with a meta-substituted biphenyl ether tail.
Experimental section
Spectrophotometric binding assay
Activity was determined as described in Blondin et al. 23 pellet was passed through a 5.0 µM filter (Millipore) to eliminate clumps and left for 1 hour to recover at 37 °C, 5% CO 2 . Next, the bacterial suspension was diluted in 7H9-10% OADC to obtain 50,000 Relative Light Units (RLU)/mL and a volume of 180 µL of bacteria was added to each well. A bacterial replication was analyzed by luminometry after 7 days of incubation. The bacterial suspension from each well was collected and transferred to a black 96-well plate to evade cross luminescence between wells. The luminescent signal was evoked by addition of the substrate for the bacterial luciferase, 1% n-decanal in ethanol to each well by the Discover multiplate reader from Promega and the light emission in each well was measured.
Molecular modeling
All molecular modeling calculations were performed using the software packages AutoDock 4.2
on Windows Cygwin and AutodockTools-1.5.6. 24 The previously reported X-ray structure of the MtbTMPK (PDB entry 1G3U) 5 was used in all docking experiments. The 2D chemical structures and PDB files of the ligands were drawn and created using ChemBioDraw 13. The PDBQT file of ligands and receptor were prepared by AutodockTools-1.5.6, which includes atomic partial charges, atom types and the information of the ligand torsional degrees. For the docking, a default grid spacing of 0.375 Å and 60 × 60 × 60 number of grid points were used, which centered the box on the active site of MtbTMPK (e.g. the typical π-π stacking between Phe-70 and thymine ring of the ligand) 9 . The Genetic Algorithm-Local Search (GA-LS) method was adopted using default settings. 50 possible conformations were generated by Autodock 4.2 for each docking. A manual selection procedure combining visual inspection in Chimera guided by the Ligplot analysis together with the predicted free energy found for each conformation was used to validate the docked conformations.
Chemical synthesis
General: Solvents were purchased from standard commercial sources and of analytical grade.
Building blocks and reagents were used as received without any further purification. TLC analysis was performed using precoated Alugram Silica Gel F254 plates (Machery-Nagel A suspension of 3-((benzyloxy)methyl)-5-methylpyrimidine-2,4(1H,3H)-dione (20, 1 eq), N-Boc-protected mesylates (1.1 eq -2 eq), potassium carbonate (1.5 eq -2 eq) was stirred at 80 ℃ overnight (compound 37 and 38) or 24 h (compound 32 and 33) under argon. The work-up procedure as well as the second step were performed as has been described for the synthesis of compound 34. ( + , 344.1969; found, 344.1973. 4.2.3 General procedure for the synthesis of final compounds 1 -12.
(R)-3-((benzyloxy)methyl)-5-methyl-1-(pyrrolidin-3-yl)pyrimidine-2,4(1H,3H)-dione
A suspension of compound 32 -38 (1 eq), substituted aromatic aldehyde (1.5 -2 eq) and sodium triacetoxyborohydride ( MeCN-90% aq. 10 mM ammonium bicarbonate → 100% MeCN over 20 min. After lyophilization, products 1 -12 were obtained as a white powder.
5-methyl-1-(1-(3-phenoxybenzyl)piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione
(1):
Following the general procedure, the use of 3-((benzyloxy)methyl)-5-methyl-1-(piperidin- + , 392.1969; found: 392.1972. 4.2.3.2 5-methyl-1-(1-(4-phenoxybenzyl) piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione (2):
Following the general procedure the use of 3-((benzyloxy)methyl)-5-methyl- + , 392.1969; found: 392.1970 . -1-(1-(3-phenoxybenzyl) piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione (3):
(R)-5-methyl
Following the general procedure the use of (R)-3-((benzyloxy)methyl)-5-methyl-1-(piperidin-3- + , 392.1969; found: 392.1970 . ee: 84.8% (Daicel Chiralpak-IA HPLC column, hexane/ethanol 80/20 as eluent). 4.2.3.4 (R)-5-methyl-1-(1-(4-phenoxybenzyl) piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione (4):
Following the general procedure the use of (R)-3-((benzyloxy)methyl)-5-methyl- + , 392.1969; found, 392.1972 . ee: 90.4% (Daicel Chiralpak-IA HPLC column, hexane/ethanol 80/20 as eluent). 4.2.3.5 (S)-5-methyl-1-(1-(3-phenoxybenzyl) piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione (5) 14a :
Following the general procedure the use of (S)-3-((benzyloxy)methyl)-5-methyl- 4.2.3.9 5-methyl-1-((1-(3-phenoxybenzyl) piperidin-3-yl)methyl)pyrimidine-2,4(1H,3H)-dione (9):
Following the general procedure, 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-3-yl)pyrimidine- + , 406.2125; 406.2142. 4.2.3.10 5-methyl-1-((1-(4-phenoxybenzyl) piperidin-3-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10): Following the general procedure, 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-3yl)pyrimidine-2,4(1H,3H)-dione (38, 118.48 + , 406.2125; found, 406.2097. 4.2.3.11 5-methyl-1-((1-(3-phenoxybenzyl) 1. 17 Hz, 1H, , 11.20 (s, 1H, NH) . 13 + , 392.1969; found, 392.1986. 4.2.3.12 5-methyl-1-((1-(4-phenoxybenzyl) pyrrolidin-3-yl)methyl)pyrimidine-2,4(1H,3H)-dione (12) : Following the general procedure, 3-((benzyloxy)methyl)-5-methyl-1-(pyrrolidin-3-
